Diadema Partners LP Phathom Pharmaceuticals, Inc. Put Options Transaction History
Diadema Partners LP
- $328 Billion
- Q2 2025
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding PHAT
# of Institutions
137Shares Held
60.5MCall Options Held
1.35MPut Options Held
1.19M-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$169 Million6.31% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$101 Million12.93% of portfolio
-
Invesco Ltd. Atlanta, GA4.14MShares$56.1 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$47.4 Million41.56% of portfolio
-
Black Rock Inc. New York, NY2.93MShares$39.7 Million0.0% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $531M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...